CVS Is Breaking Its Healthcare Empire in Two. The Split Could Reshape How Americans Get Care

CVS Health plans to separate into two publicly traded companies, unwinding part of the healthcare empire it spent years assembling. One company will keep the CVS Health name and hold Aetna, CVS Caremark, CVS Specialty, Oak Street Health, Signify Health and other healthcare services. The second will contain roughly 9,000 retail pharmacies, mail pharmacy operations, MinuteClinic, virtual care and the Health100 technology business. CVS expects to complete the tax-free separation in the first half of 2028, subject to approvals and final conditions.

The announcement matters because CVS became a leading example of vertical integration in American healthcare. The company combined a national drugstore chain, a pharmacy benefit manager, an insurer and care-delivery businesses under one corporate roof. The theory was that controlling more steps could improve coordination and lower cost. The criticism was that the same structure concentrated too much power over prescriptions, insurance networks and the prices paid by employers, patients and pharmacies.

CVS Health plans to place its retail pharmacies and community-care operations in a separate public company. Image: Phillip Pessar / Wikimedia Commons / CC BY 2.0

Under the proposed structure, current chief executive David Joyner will lead the continuing CVS Health business, which will focus on insurance, pharmacy services and care delivery. The retail company will operate the familiar stores and community clinics as a distinct organization. CVS has not yet announced every governance, capital and dividend detail. Those decisions matter because debt, cash flow and investment obligations will determine how much freedom each company actually gains after the legal separation.

Management argues that two focused companies will be easier to run and value. The health-services group can concentrate on insurance performance, specialty pharmacy and clinical care, while the retail company can address store economics, consumer experience and pharmacy operations. Investors often reward a breakup when they believe a complicated structure hides stronger individual businesses. They can also punish it if the separation reveals that shared systems and purchasing power were doing more work than management admitted.

For customers, the immediate answer is simple: nothing changes overnight. The transaction is expected to take well over a year, and people will continue using CVS pharmacies, Aetna plans and Caremark services under current arrangements. Even after the split, the companies may retain commercial relationships. A corporate boundary does not automatically change a prescription price, insurance network or store location. Those outcomes will depend on contracts, regulation and the competitive choices each new company makes.

The retail side faces difficult economics. Pharmacies handle essential services but operate with pressure from reimbursement rates, labor costs, theft, changing shopping habits and competition from supermarkets, online sellers and large chains. MinuteClinic and virtual care give the new company a broader role than a traditional drugstore, yet that opportunity requires investment. A cleaner structure may make priorities easier to see, but it does not remove the underlying pressure on pharmacy margins.

The continuing CVS Health company will face its own scrutiny. Pharmacy benefit managers negotiate drug prices and determine access for millions of patients, making them a focus for lawmakers and regulators. Aetna’s insurance performance can also swing with medical costs and membership trends. Separating the storefronts may reduce some political and operational complexity, but CVS Health will still own businesses at the center of the national argument over affordability and transparency.

The company disclosed the plan alongside stronger guidance, which complicates the idea that the breakup is an emergency rescue. CVS is presenting the separation as a strategic choice made from a position of improved performance. Investors will test that claim against future earnings, cash generation and the costs of dividing technology, real estate, brands and employees. Large separations can consume management attention for years before any promised efficiency reaches shareholders.

Workers and communities will watch a different set of details. Store closures, staffing levels and clinic investment affect neighborhoods directly, especially where CVS is one of the few remaining pharmacies. The announcement did not establish a new closure program, and it would be wrong to assume one. Still, an independent retail board may evaluate locations differently from a conglomerate that also benefits from insurance and pharmacy-service relationships. The incentives created by the new structure deserve close attention.

CVS spent nearly two decades proving how large an American healthcare company could become. Its next experiment is whether the pieces can perform better apart. The split will not, by itself, make prescriptions cheaper or care easier to navigate. It will create two management teams, two stocks and a clearer view of where profits and problems live. Between now and 2028, the most important question is not whether the breakup sounds logical. It is whether each business can show customers and investors what independence actually improves.